Cannabidiol (from hemp)

Antimitotic / Anticancer

Natural, from Cannabis sativa L.

Antigout

Chemical intermediate

Indena SpA offers a wide range of pharmaceutical products which includes thiocolchicoside b. Botanical origin: gloriosa superba l. seed. Biological activity: muscle relaxant. Contact us for more information.

Indena SpA offers a wide range of pharmaceutical products which includes valeroselect®. Botanical origin: valeriana officinalis l. rhizome and root. Biological activity: sedative. Contact us for more information.

Colchicine ph. eur. Botanical origin: gloriosa superba l. seed. Biological activity: antigout.

Colchicine usp. Botanical origin: gloriosa superba l. seed. Biological activity: antigout. 

Indena SpA offers a wide range of pharmaceutical products which includes docetaxel. Botanical origin: taxus baccata l. twig and leaf. Biological activity: anti-mitotic, anticancer. 

Paclitaxel belongs to the group of taxanes together with Docetaxel. It is marked by a powerful anticancer activity. This natural product, found as part of a National Cancer Institute program in 1962 aiming at identifying natural active compounds to potentially treat cancer, is a cell division inhibitor...

Indena SpA offers a wide range of pharmaceutical products which includes escin extract. Botanical origin: aesculus hippocastanum l. seed. Biological activity: antioedema. Contact us for more information.

Indena SpA offers a wide range of pharmaceutical products which includes escin free acid. Botanical origin: aesculus hippocastanum l. seed. Biological activity: antioedema. Contact us for more information.

Natural products can be characterized by complex structure, limited availability, and exceptional potency, whose combination makes it challenging their development as API. Success requires integration of expertise in different areas, including the construction of a sustainable supply chain for the starting biomass, the capacity to manipulate high-potency products in a GMP environment, and the versatility to strategically complement isolation with semi-synthesis, total synthesis and biotechnology. In this context, mutual thrust between the service provider company and the drug candidate owner is critical, and the successful development of the anticancer drug tigilanol tiglate will give the opportunity to address these issues.

We have a unique expertise in developing and manufacturing HPAPIs. The company is equipped with kilolabs (for clinical and small commercial batches) and large industrial suite for HPAPIs with an OEL>20 ng/m3.